For over 25 years, PharmaEssentia has been driven by a clear purpose—to improve the lives of people with MPNs and other serious diseases. Rooted in scientific innovation, our journey has been one of perseverance and progress. Today, that work is making a real impact for patients around the world.
PharmaEssentia
Biotechnology Research
Burlington, MA 18,983 followers
Better Science, Better Lives.
About us
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan, leveraging deep expertise and proven scientific principles to deliver new biologics in hematology, oncology, and immunology. Founded in 2003, PharmaEssentia is now expanding its global presence with operations in the U.S., Japan, China and Korea.
- Website
-
https://us.pharmaessentia.com
External link for PharmaEssentia
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Burlington, MA
- Type
- Public Company
- Founded
- 2003
- Specialties
- Biologics, Oncology, Rare Disease, Orphan Drugs, Orphan Disease, Drug Development, Pharmaceuticals, and Hematology
Locations
Employees at PharmaEssentia
Updates
-
Our team is looking forward to attending the Morgan Stanley Global Healthcare Conference in New York City this September! We’re excited to connect with leaders across the healthcare and investment communities, share our recent progress, and offer a look at what’s ahead. Read more: https://lnkd.in/dErbxSuw
-
-
Polycythemia vera (PV) is a rare blood cancer that can lead to serious health complications—but what causes it? Swipe through to learn how PV develops and the role of a key gene called JAK2. Explore more resources, tools, and real patient stories at: https://lnkd.in/gr2jcwYS
-
If you or a loved one are living with #polycythemiavera (PV), we invite you to join us for an upcoming PV In Focus live event. Here, you can meet others living with PV and hear from several speakers on topics like treatment options, self-advocacy, and navigating PV and your mental health. Upcoming events: • September 13th - Dallas, TX • October 4th - Chicago, IL Find out more and register here: PVInFocus.com
-
-
In this recent episode of our podcast, PV Pod: Stories from the Marrow, Dr. Lucia Masarova of MD Anderson Cancer Center and polycythemia vera (PV) patient Cheri Clark discuss the importance of shared decision making and how advocacy, education, and collaboration can improve care. Listen now: https://lnkd.in/dkr7_Sgm
-
We’re excited to announce a licensing deal with the Development Center for Biotechnology (DCB) to bring Taiwan’s first CD73 immunotherapy, DCBPR2201, into the next phase of development! This first-in-class antibody aims to transform “cold tumors” into “hot tumors,” potentially improving treatment for cancers like NSCLC, pancreatic cancer, and TNBC. We look forward to advancing it through clinical development to bring new hope to patients worldwide.
🚀 Taiwan’s First CD73 Immunotherapy Moves Toward the Global Stage! https://reurl.cc/ax4YWD 生技中心 (DCB) has officially licensed its first-in-class anti-CD73 antibody drug candidate, DCBPR2201, exclusively to PharmaEssentia Corp. (TWSE: 6446). This groundbreaking immunotherapy targets high-CD73 expression cancers like NSCLC, pancreatic cancer, and triple-negative breast cancer (TNBC). 🧬 Unlike existing treatments, DCBPR2201 is designed to convert “cold tumors” into “hot tumors,” enhancing immune response by reversing the tumor’s immunosuppressive microenvironment. With no approved CD73 therapies currently on the market, this collaboration positions Taiwan at the forefront of next-gen oncology innovation. 💡 Developed through a rigorous year-long due diligence process, PharmaEssentia plans to advance DCBPR2201 through clinical development—potentially in combination with checkpoint inhibitors—to bring new hope to patients battling hard-to-treat cancers. 🔬 Key Highlights: 🎯First-in-class CD73 immune checkpoint therapy, no global equivalents on the market. 🎯Aims to convert “cold tumors” into “hot tumors” by reversing immunosuppressive tumor environments. 🎯DCBPR2201 demonstrated strong long-acting CD73 inhibition and enhanced T-cell activation in preclinical models. 🎯High tumor-targeting precision and favorable safety profiles observed in animal studies. 🎯Co-development with checkpoint inhibitors expected for future clinical strategy. Read More：https://reurl.cc/ax4YWD ➤ Follow us for more news and Taiwan biotech ecosystem updates: https://lnkd.in/gPb8fyrt #Globalbio #Immunotherapy #CD73 #BiotechInnovation #PharmaEssentia #DCB #OncologyResearch #TaiwanBiotech #PrecisionMedicine #CancerTherapy #TNBC #NSCLC #PancreaticCancer #FirstInClass
-
-
To develop next-generation medicines, you need a facility built for the future. That’s exactly what we’ve created at the PharmaEssentia Innovation Research Center, our R&D hub just north of Boston. Our PIRC team is advancing bold science into impactful therapies, from pegylated cytokines to novel immune checkpoint inhibitors and antibody-drug conjugates. Take a closer look: https://lnkd.in/eSJGCFig
-
-
There’s still time to sign up for our September PV in Focus event! More details below.
To our #PolycythemiaVera (PV) community: we're excited to announce PV In Focus, a live event on Saturday, September 13th in Dallas, TX. If you or a loved one are living with PV, we invite you to join us, meet others living with PV, and hear from several speakers on topics like treatment options, self-advocacy, and navigating PV and your mental health. Breakfast and lunch will be served. Find out more and register here: PVInFocus.com
-
-
Time flies! In just two years, our colleagues at the PharmaEssentia Innovation Research Center (PIRC) have made incredibly strides in advancing translational research and building the foundation for our next generation of therapies. Learn more about their work: https://lnkd.in/eSJGCFig
We’re celebrating 2 years of innovation, collaboration, and scientific discovery! Thank you to our dedicated team and global partners who continue to work tirelessly to find new therapies for patients with hematologic diseases. We’re just getting started!
-
-
For Buzz, advocating for his own health and finding a specialist he could partner with were critical steps following his polycythemia vera diagnosis. Hear Buzz tell the story of his PV journey. Listen to more PV patient stories: https://lnkd.in/eRU4HPhg